Does anyone have or seen this paper? Lancet Oncology Volume 7, Issue 6, June 2006, Pages 521-523
"...possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma"
I'm not sure what the "possible" in the title means
Lancet Oncology Paper - Avastin & Metastatic ASPS
we have it in the Library
Look on the Library page, between the links there is a link to the PDF of this article
http://www.cureasps.org/bibliography/ its big, about 3 Mb.
http://www.cureasps.org/bibliography/ its big, about 3 Mb.
-
Fictional
the additional info
'F', thanks for asking the author about the follow up info - I wanted to do the same but forgot. You probably missed the article because it is not named by its published name but by the comment.
-
Fictional
Dr. Slavc was very nice about answering. This is her paraphrased answer:
She said her patient had a good response to interferon plus avastin for 9 months before the metastases started to slowly increase in size again. They tried to get Sorafenib, but there it wasn't approved for 9 months because there was no experience in children and the company didn't want to give it to kids. In the interim, they tried Gleevec, Tarceva, and rapamune in addition to interferon and avastin.
When Sorafenib was available, they switched to sorafenib, but the boy did not respond and succumbed to disease. She thought in retrospect, it may have been a better idea to add sorafenib to interferon and avastin, which was well tolerated.
She did say because he didn't respond to chemotherapy at all, she thought "the most important therapy for this type of tumor" at this time is antiangiogenic meds. But, that unfortunately most tumors eventually escape antiangiogenics or become resistant.
Her thoughts were that "interferon + avastin were definitely effective" in the "massively metastasized" patient.
Otherwise, she said perhaps Mark Kieran's protocol at Childrens in Boston (celebrex, fenofibrate, thalidomide, metronomic doses of VP16 alternated with cytoxan) might be helpful, but she hadn't ever tried it specifically with ASPS.
She said her patient had a good response to interferon plus avastin for 9 months before the metastases started to slowly increase in size again. They tried to get Sorafenib, but there it wasn't approved for 9 months because there was no experience in children and the company didn't want to give it to kids. In the interim, they tried Gleevec, Tarceva, and rapamune in addition to interferon and avastin.
When Sorafenib was available, they switched to sorafenib, but the boy did not respond and succumbed to disease. She thought in retrospect, it may have been a better idea to add sorafenib to interferon and avastin, which was well tolerated.
She did say because he didn't respond to chemotherapy at all, she thought "the most important therapy for this type of tumor" at this time is antiangiogenic meds. But, that unfortunately most tumors eventually escape antiangiogenics or become resistant.
Her thoughts were that "interferon + avastin were definitely effective" in the "massively metastasized" patient.
Otherwise, she said perhaps Mark Kieran's protocol at Childrens in Boston (celebrex, fenofibrate, thalidomide, metronomic doses of VP16 alternated with cytoxan) might be helpful, but she hadn't ever tried it specifically with ASPS.